Align Technology, Inc. ALGN
Composite 56/100; the shares have moved about 43% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 32/100 — a moderate mark against it.
Balance-sheet strength ranks 85/100 — a strong point in its favour. Quality ranks 63/100 — a moderate point in its favour. Valuation ranks 51/100 — a slight point in its favour.
Growth ranks 32/100 — a moderate mark against it. Momentum ranks 42/100 — a slight mark against it.
What the company does Align Technology designs, manufactures, and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners for orthodontic and restorative dental procedures. Its Clear Aligner segment serves teens and adults, while Imaging Systems and CAD/CAM Services segment provides digital scanning and 3D printing solutions for dental professionals.
Key financials Revenue growth 0.9% and EPS growth 0.6% reflect modest top-line recovery. Margins remain strong: gross 70.4%, operating 18.2%, net 10.0%. Profitability metrics include ROE 10.2%, ROA 7.4%, and ROCE 13.9%. Balance sheet is conservative with debt/equity 0.03 and net debt/EBITDA -1.08.
Stock health Momentum is weak: -7.04% over 3 months, -15.16% over 6 months, and -22.69% below the 52-week high. RSI(14) at 36.10 indicates oversold conditions. Sideravia scores Quality 62.7, Strength 84.6, and Valuation 51.4, with overall 56.4—average quality and fairly valued.
Price vs fair value The stock trades at a discount of 34.60% versus the analyst mean target of 208.60. - Recent 3% daily decline may reflect broader sector rotation (1-day -3.02%). - Board appointment of Quentin Blackford (2026-08-31) may signal strategic evolution. - Analyst mean target implies 34.60% upside from current price.
Looking forward Forward P/E of 14.86 and PEG of 0.15 suggest improved earnings visibility. iTero scanner adoption and Invisalign First expansion could drive mid-single-digit revenue growth. Execution risk remains tied to consumer discretionary dental spending and competitive pressure.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.